Literature DB >> 24659890

Frequency and prognostic role of mucosal healing in patients with Crohn's disease and ulcerative colitis after one-year of biological therapy.

Klaudia Farkas1, Péter László Lakatos1, Mónika Szűcs1, Éva Pallagi-Kunstár1, Anita Bálint1, Ferenc Nagy1, Zoltán Szepes1, Noémi Vass1, Lajos S Kiss1, Tibor Wittmann1, Tamás Molnár1.   

Abstract

AIM: To assess the endoscopic activity before and after a one-year period of biological therapy and to evaluate the frequency of relapses and need for retreatment after stopping the biologicals in patients with Crohn's disease (CD) and ulcerative colitis (UC).
METHODS: The data from 41 patients with CD and 22 patients with UC were assessed. Twenty-four CD patients received infliximab, and 17 received adalimumab. The endoscopic severity of CD was quantified with the simplified endoscopic activity score for Crohn's disease in CD and with the Mayo endoscopic subscore in UC.
RESULTS: Mucosal healing was achieved in 23 CD and 7 UC patients. Biological therapy had to be restarted in 78% of patients achieving complete mucosal healing with CD and in 100% of patients with UC. Neither clinical remission nor mucosal healing was associated with the time to restarting the biological therapy in either CD or UC.
CONCLUSION: Mucosal healing did not predict sustained clinical remission in patients in whom the biological therapies had been stopped.

Entities:  

Keywords:  Biological therapy; Crohn’s disease; Endoscopy; Mucosal healing; Ulcerative colitis

Mesh:

Substances:

Year:  2014        PMID: 24659890      PMCID: PMC3961969          DOI: 10.3748/wjg.v20.i11.2995

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  25 in total

1.  Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.

Authors:  Paul Rutgeerts; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; Stefan Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Stephen B Hanauer
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

2.  Results of the 2nd scientific workshop of the ECCO (IV): therapeutic strategies to enhance intestinal healing in inflammatory bowel disease.

Authors:  Alessandro Armuzzi; Gert Van Assche; Walter Reinisch; Guillaume Pineton de Chambrun; Anne Griffiths; Malgorzata Sladek; Jan C Preiss; Milan Lukas; Geert D'Haens
Journal:  J Crohns Colitis       Date:  2012-03-09       Impact factor: 9.071

3.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

4.  Classification of inflammatory bowel disease.

Authors:  J E Lennard-Jones
Journal:  Scand J Gastroenterol Suppl       Date:  1989

Review 5.  Mucosal healing in inflammatory bowel diseases: a systematic review.

Authors:  Markus F Neurath; Simon P L Travis
Journal:  Gut       Date:  2012-07-27       Impact factor: 23.059

6.  Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study.

Authors:  Casper Steenholdt; Akbar Molazahi; Mark Andrew Ainsworth; Jørn Brynskov; Ole Østergaard Thomsen; Jakob Benedict Seidelin
Journal:  Scand J Gastroenterol       Date:  2012-03-01       Impact factor: 2.423

7.  Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.

Authors:  Paul Rutgeerts; Robert H Diamond; Mohan Bala; Allan Olson; Gary R Lichtenstein; Weihang Bao; Kamlesh Patel; Douglas C Wolf; Michael Safdi; Jean Frederic Colombel; Bret Lashner; Stephen B Hanauer
Journal:  Gastrointest Endosc       Date:  2006-03       Impact factor: 9.427

8.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

9.  Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing.

Authors:  Talat Bessissow; Bart Lemmens; Marc Ferrante; Raf Bisschops; Kristel Van Steen; Karel Geboes; Gert Van Assche; Séverine Vermeire; Paul Rutgeerts; Gert De Hertogh
Journal:  Am J Gastroenterol       Date:  2012-11-13       Impact factor: 10.864

10.  Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.

Authors:  Fabian Schnitzler; Herma Fidder; Marc Ferrante; Maja Noman; Ingrid Arijs; Gert Van Assche; Ilse Hoffman; Kristel Van Steen; Séverine Vermeire; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2009-09       Impact factor: 5.325

View more
  7 in total

Review 1.  The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.

Authors:  Javier P Gisbert; Alicia C Marín; María Chaparro
Journal:  Am J Gastroenterol       Date:  2016-03-22       Impact factor: 10.864

2.  Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.

Authors:  M J Casanova; M Chaparro; V García-Sánchez; O Nantes; E Leo; M Rojas-Feria; A Jauregui-Amezaga; S García-López; J M Huguet; F Arguelles-Arias; M Aicart; I Marín-Jiménez; M Gómez-García; F Muñoz; M Esteve; L Bujanda; X Cortés; J Tosca; J R Pineda; M Mañosa; J Llaó; J Guardiola; I Pérez-Martínez; C Muñoz; Y González-Lama; J Hinojosa; J M Vázquez; M P Martinez-Montiel; G E Rodríguez; R Pajares; M F García-Sepulcre; A Hernández-Martínez; J L Pérez-Calle; B Beltrán; D Busquets; L Ramos; F Bermejo; J Barrio; M Barreiro-de Acosta; O Roncedo; X Calvet; D Hervías; F Gomollón; M Domínguez-Antonaya; G Alcaín; B Sicilia; C Dueñas; A Gutiérrez; R Lorente-Poyatos; M Domínguez; S Khorrami; C Muñoz; C Taxonera; A Rodríguez-Pérez; A Ponferrada; M Van Domselaar; M L Arias-Rivera; O Merino; E Castro; J M Marrero; M Martín-Arranz; B Botella; L Fernández-Salazar; D Monfort; V Opio; A García-Herola; M Menacho; P Ramírez-de la Piscina; D Ceballos; P Almela; M Navarro-Llavat; V Robles-Alonso; A B Vega-López; I Moraleja; M T Novella; C Castaño-Milla; A Sánchez-Torres; J M Benítez; C Rodríguez; L Castro; E Garrido; E Domènech; E García-Planella; J P Gisbert
Journal:  Am J Gastroenterol       Date:  2016-12-13       Impact factor: 10.864

Review 3.  Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal.

Authors:  Anita Annaházi; Tamás Molnár
Journal:  Gastroenterol Res Pract       Date:  2015-06-14       Impact factor: 2.260

4.  The first case of biological therapy discontinuation after a complete remission induced by maintenance therapy with adalimumab for refractory ulcerative colitis.

Authors:  Satoshi Tanida; Tsutomu Mizoshita; Keiji Ozeki; Hironobu Tsukamoto; Yoshinori Mori; Eiji Kubota; Hiromi Kataoka; Takeshi Kamiya; Takashi Joh
Journal:  J Clin Med Res       Date:  2014-11-19

5.  Are we on our way to change our mode of thinking and treating inflammatory bowel disease patients?

Authors:  Fernando Magro; Rami Eliakim
Journal:  Ann Gastroenterol       Date:  2014

6.  Low Discontinuation Rate of Infliximab Treatment in Steroid-Dependent/Refractory Crohn's Disease Patients.

Authors:  Tanay Kaymak; Federico Moriconi; Jan H Niess; Christoph Beglinger; Petr Hruz
Journal:  Inflamm Intest Dis       Date:  2018-02-21

Review 7.  Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease.

Authors:  Ray K Boyapati; Joana Torres; Carolina Palmela; Claire E Parker; Orli M Silverberg; Sonam D Upadhyaya; Tran M Nguyen; Jean-Frédéric Colombel
Journal:  Cochrane Database Syst Rev       Date:  2018-05-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.